S&P 500   4,269.40 (-0.43%)
DOW   33,322.55 (-0.55%)
QQQ   359.20 (+0.26%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   447.44 (+2.86%)
NIO   8.78 (-2.88%)
BABA   86.24 (-0.58%)
AMD   102.89 (+0.07%)
T   14.83 (-1.26%)
F   12.28 (-1.13%)
MU   67.65 (-0.56%)
CGC   0.76 (-2.96%)
GE   108.61 (-1.75%)
DIS   81.28 (+0.28%)
AMC   8.02 (+0.38%)
PFE   33.63 (+1.39%)
PYPL   58.27 (-0.33%)
NFLX   379.32 (+0.46%)
S&P 500   4,269.40 (-0.43%)
DOW   33,322.55 (-0.55%)
QQQ   359.20 (+0.26%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   447.44 (+2.86%)
NIO   8.78 (-2.88%)
BABA   86.24 (-0.58%)
AMD   102.89 (+0.07%)
T   14.83 (-1.26%)
F   12.28 (-1.13%)
MU   67.65 (-0.56%)
CGC   0.76 (-2.96%)
GE   108.61 (-1.75%)
DIS   81.28 (+0.28%)
AMC   8.02 (+0.38%)
PFE   33.63 (+1.39%)
PYPL   58.27 (-0.33%)
NFLX   379.32 (+0.46%)
S&P 500   4,269.40 (-0.43%)
DOW   33,322.55 (-0.55%)
QQQ   359.20 (+0.26%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   447.44 (+2.86%)
NIO   8.78 (-2.88%)
BABA   86.24 (-0.58%)
AMD   102.89 (+0.07%)
T   14.83 (-1.26%)
F   12.28 (-1.13%)
MU   67.65 (-0.56%)
CGC   0.76 (-2.96%)
GE   108.61 (-1.75%)
DIS   81.28 (+0.28%)
AMC   8.02 (+0.38%)
PFE   33.63 (+1.39%)
PYPL   58.27 (-0.33%)
NFLX   379.32 (+0.46%)
S&P 500   4,269.40 (-0.43%)
DOW   33,322.55 (-0.55%)
QQQ   359.20 (+0.26%)
AAPL   173.13 (+1.12%)
MSFT   318.18 (+0.77%)
META   303.54 (+1.11%)
GOOGL   133.02 (+1.65%)
AMZN   128.72 (+1.26%)
TSLA   250.67 (+0.18%)
NVDA   447.44 (+2.86%)
NIO   8.78 (-2.88%)
BABA   86.24 (-0.58%)
AMD   102.89 (+0.07%)
T   14.83 (-1.26%)
F   12.28 (-1.13%)
MU   67.65 (-0.56%)
CGC   0.76 (-2.96%)
GE   108.61 (-1.75%)
DIS   81.28 (+0.28%)
AMC   8.02 (+0.38%)
PFE   33.63 (+1.39%)
PYPL   58.27 (-0.33%)
NFLX   379.32 (+0.46%)
NYSE:MYOV

Myovant Sciences (MYOV) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$26.98
▼
$27.00
50-Day Range
$26.88
▼
$26.99
52-Week Range
$7.67
▼
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Myovant Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.1% Upside
$27.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.82) to ($1.52) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.60 out of 5 stars

Medical Sector

969th out of 969 stocks

Pharmaceutical Preparations Industry

453rd out of 453 stocks

See Top Rated MarketRank™ Stocks Here

MYOV stock logo

About Myovant Sciences (NYSE:MYOV) Stock

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.


MYOV Stock News Headlines

September 26, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
September 12, 2023 | marketwatch.com
4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chief
October 2, 2023 | Stansberry Research (Ad)
Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
August 29, 2023 | msn.com
Vivek Ramaswamy claims he is too busy campaigning to give evidence
August 29, 2023 | msn.com
2024 Presidential candidate Vivek Ramaswamy trying to duck legal battle over his biotech empire
August 28, 2023 | msn.com
EXCLUSIVE: Vivek Ramaswamy claims he is too busy campaigning for President to give evidence in multi-million dollar court case
August 28, 2023 | msn.com
Vivek Ramaswamy cites campaign to duck deposition in buyout suit
August 24, 2023 | msn.com
Bill Ackman Tells Vivek Ramaswamy How To Run For President
October 2, 2023 | Stansberry Research (Ad)
Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
August 24, 2023 | finance.yahoo.com
Uterine Fibroids Treatment Global Market Report 2023
August 21, 2023 | benzinga.com
Presidential Hopeful Ramaswamy Predicts US Recession In 2024
July 4, 2023 | uk.finance.yahoo.com
Hormone Therapy Global Market Report 2023
June 26, 2023 | finance.yahoo.com
Health in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness Month
June 22, 2023 | benzinga.com
Antibacterial Drugs Market to Reach US$ 62 Billion by 2031 | Fact.MR Report
May 18, 2023 | finance.yahoo.com
Women's Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.
May 17, 2023 | finance.yahoo.com
Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids
May 16, 2023 | marketwatch.com
Endometriosis Treatment Drugs Market Top Competitors and Prediction Till 2030
May 10, 2023 | marketwatch.com
Metastatic Prostate Cancer Treatment Market Size: Growth Dynamics from 2023 to 2031
May 8, 2023 | marketwatch.com
Menstrual Cramps Treatment Market worth growing 4.0% at a CAGR by 2027
May 8, 2023 | marketwatch.com
Global "Metastatic Prostate Cancer Treatment Market" Growth and Outlook till 2023-2030
May 2, 2023 | marketwatch.com
8-K: Day One Biopharmaceuticals, Inc.
April 27, 2023 | marketwatch.com
Prostate Cancer Treatment Market Business Expands Quickly and Will Occupy Over USD 12,152 Million by 2030
April 26, 2023 | marketwatch.com
Endometriosis Market Growth by 2031
April 25, 2023 | bizjournals.com
Myovant Sciences won 3 drug approvals and got bought out. Now it's cutting nearly 100 jobs.
April 25, 2023 | finance.yahoo.com
Leading National Prostate Cancer Nonprofit Announces Return of Annual Run/Walk Series
April 3, 2023 | finance.yahoo.com
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
March 29, 2023 | finance.yahoo.com
Endometriosis Global Market Report 2022: Rise in Demand for Novel Drugs and Hormonal Therapies Bolsters Sector
See More Headlines
Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Company Calendar

Last Earnings
10/26/2021
Today
10/02/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:MYOV
Previous Symbol
NASDAQ:MYOV
CUSIP
N/A
CIK
1679082
Web
www.myovant.com
Phone
442074003351
Fax
N/A
Employees
407
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-205,980,000.00
Net Margins
-48.47%
Pretax Margin
-42.81%
Return on Equity
N/A
Return on Assets
-39.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.57
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$230.97 million
Price / Sales
11.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.04) per share
Price / Book
-5.35

Miscellaneous

Outstanding Shares
97,240,000
Free Float
95,388,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
2.17
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • David C. Marek
    Chief Executive Officer & Director
  • Jeffrey D. Nornhold
    Senior VP-Pharmaceutical Operations & Development
  • Uneek Mehra
    Chief Financial & Business Officer
  • Juan Camilo Arjona Ferreira
    Chief Medical Officer
  • Matthew LangMatthew Lang
    Secretary, Chief Administrative & Legal Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













MYOV Stock - Frequently Asked Questions

Should I buy or sell Myovant Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MYOV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View MYOV analyst ratings or view top-rated stocks.

What is Myovant Sciences' stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price objectives for Myovant Sciences' stock. Their MYOV share price forecasts range from $27.00 to $27.00. On average, they predict the company's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for MYOV or view top-rated stocks among Wall Street analysts.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) announced its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.11. The business earned $77.90 million during the quarter, compared to analyst estimates of $72.67 million. During the same period in the prior year, the business earned ($0.75) earnings per share.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $26.98.

How much money does Myovant Sciences make?

Myovant Sciences (NYSE:MYOV) has a market capitalization of $2.62 billion and generates $230.97 million in revenue each year. The company earns $-205,980,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Myovant Sciences have?

The company employs 407 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for the company is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com.

This page (NYSE:MYOV) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -